

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
SUBMISSION OF THE REGISTRATION APPLICATION
FOR CE MARK OF JENSCLIP

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that recently, the Company has formally submitted the registration application for CE mark of JensClip, the transcatheter mitral valve repair (TMVr) system. This is another product which has successfully submitted the registration application for CE mark after the transcatheter tricuspid replacement system LuX-Valve Plus, which is an important step of the Company’s globalization strategy.

JensClip is an innovative medical device designed for the treatment of severe mitral regurgitation with easy and reliable device operation. Its claw-wedge mechanical locking design enables secure fixation at any angle, ensuring stable and reliable leaflet coaptation. It is anticipated to effectively mitigate mitral regurgitation and reduce leaflet tension. The diamond-shaped valve clip design facilitates easy retrieval and repositioning, enhancing the safety of transcatheter procedures and effectively improving both procedural safety and operational convenience. The integrated release mechanism is expected to reduce potential operational risks associated with multi-step detachment processes, effectively shortening device operation time. The innovative design of JensClip has been globally patented.

The one-year clinical follow-up results of JensClip and its application experience in challenging cases have been presented at international academic conferences including EuroPCR, TCT San Francisco, and PCR London Valves in 2025. Both the safety and efficacy indicators have demonstrated outstanding performance and received widespread attention.

At present, the National Medical Product Administration registration application in China of JensClip has been submitted and accepted with excellent one-year follow-up results, which is in the registration review stage. And JensClip has also been successfully applied in clinical practices overseas. We will actively promote the registration process of JensClip to meet a wide range of clinical needs.

Cautionary Statement: There is no assurance that the Company will ultimately successfully market and/or commercialize JensClip. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei

Executive Director and Chief Executive Officer

Hong Kong, December 28, 2025

As at the date of this announcement, the executive Director of the Company is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.